Navigation Links
Bayer/Schering-Plough/Shionogi's Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
Date:4/17/2008

Superior Bacteriological Eradication and Activity Against Antibiotic-Resistant Pathogens Earn Avelox Gold Standard Status Through

2016, According to a New Report from Decision Resources

WALTHAM, Mass., April 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy's overall clinical efficacy (defined as cure or improvement of symptoms) is the attribute that most influences primary care physicians' prescribing decisions for community-acquired pneumonia. Clinical data and expert opinion show that Bayer/Schering-Plough/Shionogi's Avelox (moxifloxacin) is similar in overall clinical efficacy to the market leader levofloxacin -- Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit. However, Avelox's advantages in bacteriological efficacy, spectrum of activity, and activity against key antibiotic-resistant pathogens earn the agent gold standard status for community acquired pneumonia.

The new report entitled Community-Acquired Pneumonia: In a Crowded Generics-Dominated Market, Room for New Agents Still Exists finds that, through 2016, there are no therapies in development that will displace Avelox as the clinical gold standard for the treatment of community-acquired pneumonia. Although levofloxacin is superior to Avelox in the areas of safety and delivery -- offering a lower incidence of dermatological reactions and a five-day course of treatment -- Avelox outperforms levofloxacin on efficacy measures such as bacteriological eradication and activity against penicillin-resistant Streptococcus pneumoniae and Methicillin-resistant Staphylococcus aureus.

"Based on available data and expert opinion, we do not expect any therapy under development for community-acquired pneumonia to displace Avelox as the clinical gold standard for this indication through 2016," said John Lebbos, M.D. director at Decision Resources. "While some therapies in development for community-acquired pneumonia hold promise, most of them have efficacy, safety and/or delivery features that are inferior when compared with Avelox."

About the Report

Community-Acquired Pneumonia: In a Crowded Generics-Dominated Market, Room for New Agents Still Exists is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com ) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
2. Cord Blood America Supports Trend From New York, California for States to Inform Parents of the Advantages of Umbilical Cord Blood Storage
3. Creative work has health advantages, Population Research Center study shows
4. Presentation at ISSN Highlights Soy Protein Advantages for Endurance Athletes
5. New Celebrity Introduces Students to Need, Advantages of Health Care Careers
6. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
7. MRI before surgery leads to better-adapted treatment for breast cancer
8. Obese women disadvantaged in both breast cancer treatment and diagnosis
9. Alcons PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
10. Extra Drug Improves Rectal Cancer Treatment
11. Combining liver cancer treatments doubles survival rates, UVA researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology: